FDA genetics panel
This article was originally published in The Gray Sheet
Agency announces in a Sept. 27 Federal Register notice the formation of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee in the Center for Devices and Radiological Health and requests nominations for members to serve on the panel. Nominations of persons having expertise in human genetics, clinical management of patients with genetic disorders, training in biochemical and/or molecular genetics and experience in genetic counseling and medical ethics are due by October 27. The panel will be charged with providing advice to the FDA commissioner on appropriate scientific criteria to diagnostically test for human genes
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.